Stay updated on Gemcitabine+Nivolumab in Metastatic Small Cell Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Gemcitabine+Nivolumab in Metastatic Small Cell Lung Cancer Clinical Trial page.

Latest updates to the Gemcitabine+Nivolumab in Metastatic Small Cell Lung Cancer Clinical Trial page
- Check2 days agoChange DetectedThe ClinicalTrials.gov site revision label was updated from v3.8.0 to v3.8.1.SummaryDifference0.1%

- Check9 days agoChange DetectedThe clinical-trial record is available with its study design, eligibility criteria, treatments, outcomes, and supporting documents. It identifies the trial as terminated and no longer seeking participants.SummaryDifference54%

- Check16 days agoChange DetectedThe footer’s site revision changed from v3.7.2 to v3.8.0; the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check30 days agoChange DetectedA banner announces NIH website transition updates and says “Super Intelligence” is being used in place of “Artificial Intelligence.” The site revision changed from v3.7.1 to v3.7.2, while the study page still displays a 403 error.SummaryDifference1%

- Check44 days agoChange DetectedThe footer’s ClinicalTrials.gov revision identifier changed from v3.7.0 to v3.7.1. The study page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check58 days agoChange DetectedThe study record page now shows a 403 Forbidden error instead of the expected trial content, with a Home link shown in the header/footer indicating the content is temporarily unavailable.SummaryDifference19%

Stay in the know with updates to Gemcitabine+Nivolumab in Metastatic Small Cell Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Gemcitabine+Nivolumab in Metastatic Small Cell Lung Cancer Clinical Trial page.